Discovery of BI 224436, a noncatalytic site integrase inhibitor (NCINI) of HIV-1

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 422-427

  Fader, Lee D ^a,b   Malenfant, Eric ^a   Parisien, Mathieu ^a   Carson, Rebekah ^a   Bilodeau, François ^a   Landry, Serge ^a   Pesant, Marc ^a   Brochu, Christian ^a   Morin, Sébastien ^a   Chabot, Catherine ^a   Halmos, Ted ^a   Bousquet, Yves ^a   Bailey, Murray D ^a   Kawai, Stephen H ^a,c   Coulombe, René ^a   Laplante, Steven ^a   Jakalian, Araz ^a   Bhardwaj, Punit K ^a,d   Wernic, Dominik ^a,e   Schroeder, Patricia ^a,f   Amad, Ma'An ^a   Edwards, Paul ^a   Garneau, Michel ^a   Duan, Jianmin ^a   Cordingley, Michael ^a   Bethell, Richard ^a   Mason, Stephen W ^a,g   Bös, Michael ^a   Bonneau, Pierre ^a   Poupart, Marc André ^a   Faucher, Anne Marie ^a   Simoneau, Bruno ^a   Fenwick, Craig ^a   Yoakim, Christiane ^a   Tsantrizos, Youla ^a,h   more..

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c Gina Cody School of Engineering and Computer Science   (Canada)

^d BRISTOL MYERS SQUIBB   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f EMD Serono   (United States)

^g Toronto Research Chemicals Inc   (Canada)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

allosteric inhibitor; HIV Integrase; LTR DNA 3 processing; NCINI

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BI 224436; INTEGRASE; INTEGRASE INHIBITOR; QUINOLINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; BINDING SITE; CLINICAL TRIAL (TOPIC); DRUG CYTOTOXICITY; DRUG POTENCY; HUMAN; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; SERUM; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

EID: 84898052087     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500002n     Document Type: Article

References (28)

1. World Health Organization. Factsheet No. 360, updated June30, (2013. http://www.who.int/mediacentre/factsheets/fs360/en/index.html (accessed July 14, 2013).
2. Palella, F. J., Jr.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N. Engl. J. Med. 1998, 338, 853-860
3. Carr, A.; Cooper, D. A. Adverse effects of antiretroviral therapy Lancet 2000, 356, 1423-1430
4. Reisler, R. B.; Han, C.; Burman, W. J.; Tedaldi, E. M.; Neaton, J. D. Grade 4 events are as important as AIDS events in the era of HAART J. Acquired Immune Defic. Syndr. 2003, 34, 379-386
5. Clavel, F.; Hance, A. J. HIV drug resistance N. Engl. J. Med. 2004, 350, 1023-1035
6. Craigie, R. The molecular biology of HIV integrase Future Virol. 2012, 7, 679-686
7. McColl, D. J.; Chen, X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy Anti-Viral Res. 2010, 85, 101-118
8. Raffi, F.; Wainberg, M. A. Multiple choices for HIV therapy with integrase strand transfer inhibitors Retrovirology 2012, 9, 110
9. Arribas, J. R.; Eron, J. Advances in antiretroviral therapy Curr. Opin. HIV AIDS 2013, 8, 341-349
10. Calin, R.; Katlama, C. The place of raltegravir in the clinical management of HIV-1 infection Clin. Pract. 2013, 10, 427-438
11. For the first disclosure of the synthesis and biological activity of this series of inhibitors see: Tsantrizos, Y. S.; Boes, M.; Brochu, C.; Fenwick, C.; Malenfant, E.; Mason, S.; Pesant, M. Inhibitors of Human Immunodeficiency Virus Replication PCT Int. Appl. WO 2007/131350.
12. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Engelman, A.; Craigie, R.; Davies, D. R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases Science 1994, 266, 1981-1986
13. Molteni, V.; Greenwald, J.; Rhodes, D.; Hwang, Y.; Kwiatkowski, W.; Bushman, F. D.; Siegel, J. S.; Choe, S. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain Acta Crystallogr., Sect. D: Biol. Crystallogr. 2001, 57, 536-544
14. Cherepanov, P.; Ambrosio, A. L.; Rahman, S.; Ellenberger, T.; Engelman, A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17308-17313
15. Maertens, G.; Cherepanov, P.; Pluymers, W.; Busschots, K.; De Clercq, E.; Debyser, Z.; Engelborghs, Y. LEDGF/p75 Is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells J. Biol. Chem. 2003, 278, 33528-33539
16. Fenwick, C.; Bethell, R.; Bonneau, P.; Duan, J.; Faucher, A.-M.; Mason, S.; Poupart, M.-A.; Simoneau, B.; Tsantrizos, Y.; Yoakim, C. Identification of BI-C, a novel HIV-1 non-catalytic site integrase inhibitor. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 27 February-3 March, 2011 (abstract 523).
17. Simoneau, B.; Amad, M.; Bailey, M. D.; Bethell, R.; Bhardwaj, P. K.; Bilodeau, F.; Bonneau, P.; Bös, M.; Bousquet, Y.; Brochu, C.; Carson, R.; Chabot, C.; Cordingley, M.; Coulombe, R.; Duan, J.; Edwards, P.; Fader, L.; Faucher, A.-M.; Fenwick, C.; Garneau, M.; Halmos, T.; Jakalian, A.; Kawai, S.; Landry, S.; Laplante, S.; Malenfant, E.; Mason, S.; Morin, S.; Parisien, M.; Pesant, M.; Poupart, M.-A.; Tsantrizos, Y.; Wernic, D.; Yoakim, C. Identification of Novel Non-Catalytic Site Integrase Inhibitors (NCINIs) of LTR DNA 3′ Processing. 24th International-Conference on Antiviral Research, Sofia, Bulgaria, May 8-11th, 2011, (Late Breaker abstract).
18. 50 determinations were made as previously described: Rajotte, D.; Tremblay, S.; Pelletier, A.; Salois, P.; Bourgon, L.; Coulombe, R.; Mason, S.; Lamorte, L.; Sturino, C. F.; Bethell, R. Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series Antimicrob. Agents Chemother. 2013, 57, 2712-2718
19. Christ, F.; Voet, A.; Marchand, A.; Nicolet, S.; Desimmie, B. A.; Marchand, D.; Bardiot, D.; Van der Veken, N. J.; Van Remoortel, B.; Strelkov, S. V.; De Maeyer, M.; Chaltin, P.; Debyser, Z. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication Nat. Chem. Biol. 2010, 6, 442-448
20. Feng, L.; Sharma, A.; Slaughter, A.; Jena, N.; Koh, Y.; Shkriabai, N.; Larue, R. C.; Patel, P. A.; Mitsuya, H.; Kessl, J. J.; Engelman, A.; Fuchs, J. R.; Kvaratskhelia, M. The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors J. Biol. Chem. 2013, 288, 15813-15820
21. Bailey, M. D.; Bilodeau, F.; Carson, R. J.; Fader, L.; Halmos, T.; Kawai, S.; Landry, S.; Laplante, S.; Simoneau, B.; Tsantrizos, Y. S. Inhibitors of Human Immunodeficiency Virus Replication. PCT Int. Appl. WO 2009/062289
22. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus Virology 1998, 250, 255-262
23. Balakrishnan, M.; Yant, S. R.; Tsai, L.; O'Sullivan, C.; Bam, R. A.; Tsai, A.; Niedziela-Majka, A.; Stray, K. M.; Sakowicz, R.; Cihlar, T. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells PLoS One 2013, 8, e74163-e74163
24. Jurado, K. A.; Wang, H.; Slaughter, A.; Feng, L.; Kessl, J. J.; Koh, Y.; Wang, W.; Ballandras-Colas, A.; Patel, P. A.; Fuchs, J. R.; Kvaratskhelia, M.; Engelman, A. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 8690-8695
25. Feng, L.; Sharma, A.; Slaughter, A.; Jena, N.; Koh, Y.; Shkriabai, N.; Larue, R. C.; Patel, P. A.; Mitsuya, H.; Kessl, J. J.; Engelman, A.; Fuchs, J. R.; Kvaratskhelia, M. The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors J. Biol. Chem. 2013, 288, 15813-15820
26. Christ, F.; Shaw, S.; Demeulemeester, J.; Desimmie, B. A.; Marchand, A.; Butler, S.; Smets, W.; Chaltin, P.; Westby, M.; Debyser, Z.; Pickford, C. Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization Antimicrob. Agents Chemother. 2012, 56, 4365-4374
27. Tsiang, M.; Jones, G. S.; Niedziela-Majka, A.; Kan, E.; Lansdon, E. B.; Huang, W.; Hung, M.; Samuel, D.; Novikov, N.; Xu, Y.; Mitchell, M.; Guo, H.; Babaoglu, K.; Liu, X.; Geleziunas, R.; Sakowicz, R. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action J. Biol. Chem. 2012, 287, 21189-21203
28. Kessl, J. J.; Jena, N.; Koh, Y.; Taskent-Sezgin, H.; Slaughter, A.; Feng, L.; de Silva, S.; Wu, L.; Le Grice, S. F. J.; Engelman, A.; Fuchs, J. R.; Kvaratskhelia, M. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors J. Biol. Chem. 2012, 287, 16801-16811